Project Grant R01CA296807
Award Date
12/1/24
Completion Date
11/30/29
Dollars Obligated
$627K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Chapel Hill, NC 27599, USA
Similar Awards
This $400,000 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports the development of next-generation chimeric antigen receptor T-cell (CAR-T) therapy for renal cell carcinoma (RCC). The project aims to evaluate whether the combination of two genetic modifications - PRDM1 exon 3 knockout and CTLA-4 cytoplasmic tail fusion - can enhance the anti-tumor activity of ENPP3-targeted CAR-T cells against RCC compared to either...
This $1,220,394 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports a comprehensive study of the acute and chronic neurotoxicity associated with chimeric antigen receptor (CAR) T-cell therapy for hematologic malignancies.
The research aims to investigate the molecular mechanisms underlying immune effector cell-associated neurotoxicity syndrome (ICANS), a common neurological complication of CAR-T cell therapy, as well...
This $1,271,780 federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research to develop small molecule adaptors for reprogramming universal chimeric antigen receptor (CAR) T cells. The primary objectives are to: 1) create small molecule adaptors to target universal CAR T cells to multiple antigens, including tumor cells and immunosuppressive cells; 2) enhance CAR targeting specificity using chemical switches...
This federal Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $406,249 to The Trustees of the University of Pennsylvania to conduct research on the response and resistance to chimeric antigen receptor (CAR) T cell therapy in human solid tumors.
The primary objectives are to: 1) define the tumor and stromal features that influence CAR T cell tumor infiltration and function; 2) determine...
The National Cancer Institute (NCI) has awarded a $587,108 Project Grant under the Cancer Biology Research program (CFDA 93.396) to The Trustees of the University of Pennsylvania, doing business as Clinical Practices of the University of Pennsylvania. The grant aims to enhance the efficacy and durability of chimeric antigen receptor (CAR) T cell immunotherapy by modulating interferon type I (IFN1) signaling in non-activated T cells.
The key goals of this 5-year research project are to: 1)...
The National Cancer Institute (NCI) awarded a $609,749 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to the University of North Carolina at Chapel Hill (UNC-CH) to develop a novel combination therapy for the treatment of glioblastoma multiforme (GBM), the most aggressive form of brain cancer. The key objectives are to: 1) Create an injectable, biodegradable hydrogel scaffold that can deliver high concentrations of induced neural stem cells (iNSCs) for...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $652,725 to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct a Phase I clinical trial of a novel cellular immunotherapy called CARV3.TEAM-E cells for the treatment of glioblastoma, a deadly brain cancer. The CARV3.TEAM-E cells are engineered CAR-T cells that secrete a T cell-engaging antibody molecule to more effectively target tumor...
This Project Grant award of $218,089 from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports the development and evaluation of a novel CAR-macrophage (CAR-M) immunotherapy targeting triple-negative breast cancer (TNBC). The University of California, Santa Barbara (UCSB) will conduct this research to optimize the tumor-infiltrating and phagocytic capabilities of anti-CSPG4 RAC-enhanced CAR-Ms (RACE-CAR-Ms) in the TNBC microenvironment. Key objectives include...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $655,700.00 in funding to the University of California, San Diego (UCSD) to translate a fluorine-19 (19F) MRI technology to visualize tumor-associated macrophages (TAMs) in patients with recurrent head and neck squamous cell carcinoma (HNSCC).
The key objectives are to: 1) develop a novel perfluorocarbon nanoemulsion formulation ("TAM-SENSE") suitable for a...
The National Cancer Institute (NCI) awarded a $235,417 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the University of California, San Diego (UCSD) to identify splice variant-derived neoantigens as targets for tumor vaccine therapy in head and neck squamous cell carcinoma (HNSCC). The 5-year grant will fund research to predict and prioritize splice variant-derived peptides, evaluate their immunogenicity in a murine oral cancer model, and incorporate promising...